Up-titrated 2mg Ozempic associated with lower cardiovascular risk than Mounjaro switch in type 2 diabetes, study finds

Two retrospective studies using United States healthcare data were filed on October 12, 2026.

Sarah Lindqvist-Park

Clinical Nutrition Writer

Share on X

Stands on 2 placed sources from 2 publishers.

Study finds Ozempic dose increase lowers cardiovascular risk AI illustrationhow this picture was made

A retrospective observational study using US healthcare claims data found patients with type 2 diabetes increasing Ozempic dose to 2mg had 6% lower major adverse cardiovascular event risk than those switching to Mounjaro. ^[1] The study was filed October 12, 2026. A retrospective cohort study linked data from the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness registry to Medicare claims from 2015 to 2021. ^[2] This work was filed on the same date.

Proof2 sources · 2 publishers · signed

What this stands on

A retrospective observational study using US healthcare claims data found patients with type 2 diabetes increasing Ozempic dose to 2mg had 6% lower major adverse cardiovascular event risk than those switching to Mounjaro. · Healthline Media
A retrospective cohort study linked data from the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness registry to Medicare claims from 2015 to 2021. · healio.com

We could not place any of them by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.